Actively Recruiting
Antihistamines, Amantadine and Evolution of COVID-19
Led by Consorci Sanitari de Terrassa · Updated on 2026-04-03
140660
Participants Needed
2
Research Sites
416 weeks
Total Duration
On this page
Sponsors
C
Consorci Sanitari de Terrassa
Lead Sponsor
I
Institut Català de la Salut
Collaborating Sponsor
AI-Summary
What this Trial Is About
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
CONDITIONS
Official Title
Antihistamines, Amantadine and Evolution of COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients having chronic treatment with antihistamines or amantadine
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospital de Terrassa
Terrassa, Barcelona, Spain, 08227
Actively Recruiting
2
Hospital of Terrassa
Terrassa, Barcelona, Spain, 08227
Actively Recruiting
Research Team
A
Anna Puigdellivol, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here